Urinary Extracellular vesicles abundance of SLC12A3 (NCC) increase and Aquaporine2 decrease following DASH diet implementation

Dana Bielopolski; Luca Musante; Henrik Molina; Douglas Barrows; Thomas Carrol; Jonathan N. Tobin; Rhonda. G Kost; U Erdbruegger

doi:10.1101/2022.11.29.22282878

Abstract

The Dietary Approach to Stop Hypertension (DASH) diet is a proven intervention to treat hypertension, yet its mechanism is not clearly known. We investigated the change in protein abundance patterns in urine extracellular vesicles (uEV’s) following DASH diet implementation.

A pilot study was carried out to compare uEVs isolated using three different methods: a low centrifugation (P20), high centrifugation (P100), and a combination of both (P20 and P100). Uromodulin was removed by size exclusion chromatography and low ionic strength washing. Mass spectrometry analysis identified 1,593 proteins in the combined fraction (P20+P100), 1434 in the P20 fraction and 1229 in the P100 fraction. The combined fraction was chosen for further analysis. Statistical analysis was carried out using R and Limma to identify all proteins that changed before and during 11 days of DASH intervention (p < 0.05) as well as between individual timepoints.

Nine hypertensive volunteers were admitted for a 14-day supervised transition from American style diet to DASH diet. First-void urine was collected on days 0, 5, 11 for uEV processing. In total, 1800 proteins were identified across all 27 DASH samples with 22 proteins upregulated and 25 down regulated between day 0 and both days 5 and 11. These included increased abundance of SLC12A3 (NCC) and reduced abundance of Aquaporine 2.

These changes could explain the increased urine volume and reduced sodium reabsorption that lead to blood pressure reduction following consumption of the high potassium and low sodium DASH diet. uEVs may serve as a surrogate to a more invasive procedure.

Translational Statement Myriad studies have characterized blood pressure reduction following DASH diet implementation, yet its precise mechanism is unclear. Here, we demonstrate for the first time the effect of DASH nutritional changes, on kidney ion channel composition using proteomic analysis of urinary EVs. Using this innovative tool as a substitute for an invasive procedure, we show that the expression of Aquaporine2 increases and NCC decreases in response to DASH which may account for its antihypertensive effect. Our results indicate that urinary EV are a potential biomarker for DASH compliance, and targeting aquaporine2 may be an effective innovative therapeutic strategy for blood pressure reduction.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04142138

Funding Statement

This work was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University, Grant #UL1TR001866. This work was supported by the Young Investigator Grant of the National Kidney Foundation

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Rockefeller University IRB approved this trial

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Funding: This trial was funded by the Young Investigator award of the National Kidney Foundation. This publication was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University, Grant # UL1 TR001866.